A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants

Study Identifier:
ALXN1210-HV-102
ClinicalTrials.gov Identifier:
NCT05288673
EudraCT Identifier:
2014-005495-29
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: ALXN1210
  • Drug: Placebo
Date
Jul 2015 - Sep 2016
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 25 - 55 Years
Requirements Information
Sex
Female & Male
Age
25 - 55 Years

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: ALXN1210
  • Drug: Placebo
Date
Jul 2015 - Sep 2016
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 25 - 55 Years years
Requirements Information

Protocol Summary

This study evaluated the safety and tolerability of multiple doses of ALXN1210 (400 and 800 milligrams \[mg\]) following intravenous (IV) administration to healthy participants.

Trial Locations

Location
Status
Location
Clinical Trial Site
London, United Kingdom
Status
N/A